• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Appoints Three to Its Board of Directors

    8/20/21 8:00:00 AM ET
    $COO
    $OM
    $SGHT
    Ophthalmic Goods
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $COO alert in real time by email

    Holly Sheffield, Medical Technology Executive and Investment Banker

    Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader

    James Rogers, Public and Private Medical Technology Investor

    Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers.

    "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients' needs in the fields of stroke and peripheral vascular disease."

    After a distinguished career of more than 20 years in investment banking, Holly Sheffield joined CooperCompanies (NYSE:COO) as Executive Vice President, Chief Strategy Officer in June of 2018. Last year, Holly was named President of CooperSurgical, one of Cooper Companies' two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was Managing Director and Global Head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a Managing Director until 2009. Holly is a graduate of Cornell University and obtained her MBA from Columbia University.

    Before transitioning to the world of venture capital, Hank Plain began his highly successful career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous Boards including Nuvaira, Moximed, Earlens and Setpoint. He also serves as Chairman of the Board of Trustees for the Naval Postgraduate School Foundation and on the Future Citizens Foundation/First Tee Board. He is a graduate of the University of Missouri with a B.S. in Finance.

    James Rogers is an Analyst at D1 Capital Partners, the lead investor in Imperative Care's $260 million Series D financing announced last month. Since D1 launched in July 2018, James has led over a dozen private financings, including investments in innovative medical technology companies such as Auris Health, Outset Medical (NASDAQ:OM), and Sight Sciences (NASDAQ:SGHT). Previously, he was a Principal at Valinor Management and an Analyst at The Blackstone Group. James graduated from the University of Virginia with a B.S. in Commerce and a B.A. in History as a Jefferson Scholar and an Echols Scholar.

    "Imperative Care's intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a Board with a long-term horizon and broad expertise. Holly, Hank and James will further strengthen the tremendous prowess of the existing Imperative Care Board, to help achieve this important mission. We are delighted to have them on the team," said John Hamre, Ph.D., Chairman of the Nominating and Governance Committee of the Imperative Care's Board of Directors.

    About Imperative Care, Inc.

    Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two 510(k) cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care's wholly owned subsidiary, Truvic Medical, Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.

    For more information, visit www.imperativecare.com and www.truvic.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005043/en/

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO
    $OM
    $SGHT

    CompanyDatePrice TargetRatingAnalyst
    The Cooper Companies Inc.
    $COO
    8/28/2025$72.00Buy → Neutral
    Citigroup
    Sight Sciences Inc.
    $SGHT
    8/8/2025$5.00Hold → Buy
    Lake Street
    The Cooper Companies Inc.
    $COO
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    The Cooper Companies Inc.
    $COO
    6/17/2025$94.00Hold → Buy
    Needham
    The Cooper Companies Inc.
    $COO
    5/30/2025$76.00Overweight → Neutral
    Analyst
    Sight Sciences Inc.
    $SGHT
    12/6/2024$5.50Buy
    UBS
    Sight Sciences Inc.
    $SGHT
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    The Cooper Companies Inc.
    $COO
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    More analyst ratings

    $COO
    $OM
    $SGHT
    SEC Filings

    View All

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    8/28/25 4:18:56 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    8/27/25 4:25:57 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure

    8-K - Sight Sciences, Inc. (0001531177) (Filer)

    8/27/25 4:05:06 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

    MENLO PARK, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that UnitedHealthcare (UHC) has updated its Glaucoma Surgical Treatments policy to cover goniotomy, trabeculotomy, canaloplasty (ab interno), and combined canaloplasty (ab interno) and trabeculotomy procedures for adults (age 19 years or more), when deemed medically necessary for treating mild to moderate open-angle glaucoma (OAG) and cataract in adults currently being treated with ocular

    9/9/25 7:05:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Northwest Kidney Centers and Outset Medical Announce Collaboration to Grow Home Hemodialysis

    SAN JOSE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Northwest Kidney Centers, the first organization to establish a home hemodialysis program, today announced a collaboration with Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company transforming the dialysis experience across the continuum of care. Through the collaboration, Northwest Kidney Centers will add Outset's Tablo Hemodialysis System to its offerings for patients in its network with the shared goal to expand access to home hemodialysis. With one of the largest and oldest home dialysis programs in the country, Northwest Kidney Centers has long championed patient independence and flexibility. Currently, nearly

    9/3/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

    MENLO PARK, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company) an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that its TearCare System, has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology. "For the first time, TearCare has been officially included in the TFOS DEWS III Management and Therapy Report, widely recognized as one of the primary standards in evidence-based dry eye disease m

    9/2/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO White Albert G Iii bought $683,900 worth of shares (10,000 units at $68.39), increasing direct ownership by 5% to 226,151 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 5:10:48 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President, CooperVision, Inc. Warner Gerard H Iii bought $100,384 worth of shares (1,450 units at $69.23), increasing direct ownership by 9% to 18,319 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 4:07:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    EVP, Operations & R&D Taylor Brenton was granted 25,840 shares, increasing direct ownership by 16% to 185,840 units (SEC Form 4)

    4 - Sight Sciences, Inc. (0001531177) (Issuer)

    9/3/25 4:23:56 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO White Albert G Iii bought $683,900 worth of shares (10,000 units at $68.39), increasing direct ownership by 5% to 226,151 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 5:10:48 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    President, CooperVision, Inc. Warner Gerard H Iii bought $100,384 worth of shares (1,450 units at $69.23), increasing direct ownership by 9% to 18,319 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/5/25 4:07:15 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    EVP & Chief Operating Officer Mcbride Daniel G bought $195,120 worth of shares (3,000 units at $65.04), increasing direct ownership by 5% to 63,120 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    9/2/25 5:17:03 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $OM
    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper downgraded by Citigroup with a new price target

    Citigroup downgraded Cooper from Buy to Neutral and set a new price target of $72.00

    8/28/25 8:04:41 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences upgraded by Lake Street with a new price target

    Lake Street upgraded Sight Sciences from Hold to Buy and set a new price target of $5.00

    8/8/25 8:25:35 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Cooper upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

    7/22/25 7:47:24 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    $OM
    $SGHT
    Leadership Updates

    Live Leadership Updates

    View All

    Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

    SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

    5/14/25 9:00:00 AM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences Appoints Gary Burbach to its Board of Directors

    MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

    4/22/25 4:05:00 PM ET
    $BWXT
    $SGHT
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    $COO
    $OM
    $SGHT
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Third Quarter 2025 Results

    SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 or 15% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' Presiden

    8/27/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

    MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the second quarter ended June 30, 2025, and raised its revenue guidance while reaffirming its adjusted operating expense guidance, both for full year 2025. Recent Financial and Business Highlights Generated second quarter 2025 total revenue of $19.6 million, a decrease of 8% compared to the same period in the prior year. This expected decline was primarily due to low

    8/7/25 4:05:00 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

    SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the second quarter ended June 30, 2025. Second Quarter and Recent Highlights Net revenue of $31.4 million grew 15% from the prior-year period, driven by a 25% increase in Tablo console revenue.Recurring revenue consisting of Tablo consumables and services grew 11% over the prior-year period to $22.5 million, driven by a 17% increase in consumable revenue.Gross margin was 37.8%, or 38.4% on a non-GAAP basis, a 110 basis-point improvement over the prior

    8/6/25 4:02:00 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $COO
    $OM
    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

    SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

    11/14/24 11:57:36 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:53:46 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

    SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

    11/12/24 4:26:01 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care